Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG Topic: Medical Device

Medical Devices are manmade perishable and nonperishable instruments used in healthcare. There are several types of devices: surrogates that supplement a normal human function (e.g. artificial discs); diagnostic machine that assesses health (e.g. a magnetic resonance imaging machine, or MRI); and assistive products designed to improve procedural safety and efficacy (e.g. robotic surgical systems).

Request a consultation







Leading Experts: Medical Device

What is a GLG Leader?
Stephen Li, PhD, President, Medical Device Testing and Innovations, LLCStephen Li, PhD
President
Medical Device Testing and Innovations, LLC

Stephen Li, PhD, is the President of Medical Device Testing and Innovations, LLC. Dr. Li has vast experience in biomechanics, orthopedics and biomaterials. He has a PhD in Chemistry and has worked in the area of biomedical materials and devices for over 20 years. He has worked on the development of...

John Ryan, Partner, CROWELL & MORING LLPJohn Ryan
Partner
CROWELL & MORING LLP

John W. Ryan is a Partner at Crowell & Moring in Washington, DC, where he focuses on the chemical, biotechnology, medical device, and pharmaceutical industries. As the former Vice President and Chief Patent Counsel for IGEN International, he has managed various patent portfolios. Previously, Mr. Ryan...

Peter Culpepper, CPA, MBA, Chief Financial Officer, Provectus Pharmaceuticals, Inc.Peter Culpepper, CPA, MBA
Chief Financial Officer
Provectus Pharmaceuticals, Inc.

Peter Culpepper is the Chief Financial Officer at Provectus Pharmaceuticals. Mr. Culpepper has experience in medical device, biotech, healthcare OTC, specialty pharma and, therapeutic products. Previous to that, Mr. Culpepper served as the Chief Financial Officer at Felix Culpepper International, Inc....

Deborah Outlaw, JD
Principal
THE OUTLAW GROUP

Deborah Outlaw is the Principal of The Outlaw Group in Washington, DC, where she provides legislative, regulatory and medical coding services to physician specialty groups, allied health providers, medical device manufacturers, and non-profit organizations interested in medical research. With over 25...

Thomas Saunders, Partner, SEYFARTH SHAW LLPThomas Saunders
Partner
SEYFARTH SHAW LLP

Thomas Saunders is a Partner at Seyfarth Shaw in Boston, Massachusetts, where he specializes in representing emerging medical technology, biotechnology/genetic engineering and pharmaceutical concerns, particularly as to patent prosecution, patent strategy, IP licensing matters and ANDA Paragraph IV...

View All GLG Leaders in Healthcare

GLG NewsSM Analysis: Medical Device(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
More oversight to foil bribes is wishful thinking | 04-07-2008
Analysis of: New Focus of Inquiry Into Bribes: Doctors | www.nytimes.com
Author: Robert Forster, Healthcare Consultant, Robert Forster, MD

Illegal and unethical bribes to orthopedists have gone on since time immemorial and have been visible throughout the medical and device profession and business.  Yet little (despite Peter Robert Stark's attempt) to separate this added incentive from the most highly paid specialists in medicine,...

Cubicin not tainted but delivery device. | 04-14-2008
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: GLG Expert Contributor

            ReadyMED® is a infusion device used primarily in outpatient settings for administering antiobiotics in the home.  ReadyMED® requires little patient or caregiver training and works by gravity.  No IV poles or pumps...

Aspect Medical Systems in the Spotlight- The Bis Monitor, Medical Need and The Capital Markets | 03-28-2008
Analysis of: Anesthesia Awareness and the Bispectral Index | content.nejm.org
Author: Jason Campagna, MD,PhD, Director of Clinical Quality and Analytics, COTTAGE HEALTH SYSTEM

1. The market for "depth of anesthesia" monitors has depended very much on marketing and public perception of the problem. This article shines a bright light on the more objective issues of utility and efficacy. 2. Aspect Medical has made a number of mis-steps over the years that have alienated them...

Who to Blame for Waste in the Medical Industry? Who's on First? | 04-30-2008
Author: Joe Atkins, RN, MBA, CNN, CHT, Chief Executive Officer, Medical Concepts & Innovations

It's easy to point fingers of blame and this article does that, very well.  According to the "annalysis" everybody is to blame.  And, they're right, everyone is to blame, but where the article fails is the authoris inability to point out a real solution to the problem of wasted dollars spent...

Fees, fines, foes and fun - Mobile device and wireless equipment and chipset suppliers | 04-17-2008
Analysis of: Qualcomm the big question mark in 4G cross-licensing | telephonyonline.com
Author: GLG Expert Contributor

It remains to be seen what role mobile operators will play in knocking together the heads of their equipment and device suppliers as well as chipset vendors and technology developers so they can deploy next generation wireless technologies when they want/need to at reasonable cost. 

View All GLG News in Healthcare

GLG InstituteSM Seminars: Medical Device(?)

 
Recent Seminars
View All View all GLG InstituteSM Seminars in in Healthcare

Quick Facts about GLG

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics